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Alogliptin (AGLT), active ingredient of Alogliptin Benzoate (AGLT-BZ), is a new dipeptidyl
peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes. This study aimed to build
a suitable method to determine the potential related substances in AGLT-BZ bulk drug and
tablets. Seven related substances in Alogliptin Benzoate substances were synthetized and
identified by 1H-NMR and ESI-MS. In addition, the impurities were detected by a gradient
reverse-phase high performance liquid chromatography (RP-HPLC) with UV detection. The
chromatographic system consisted of an Angilent Zobax SB-CN column (250  4.6 mm;
5 mm). The mobile phase consisted of water/acetonitrile/trifluoroacetic acid 1900:100:1 v/v/
v (solution A) and acetonitrile/water/trifluoroacetic acid 1900:100:1 v/v/v (solution B) using
a gradient program at a flow rate of 1.0 ml/min with 278 nm detection and an injection
volume of 20 ml. Additionally, selectivity, the limit of quantitation (LOQ) and limit of
detection (LOD), linearity, accuracy, precision and robustness were determined. Linearity
was good over the concentration range 50e1000 ng/ml and the coefficient of determination
(R2) were 0.9991e0.9998. RSD% of the determination of precision were <2% (n ¼ 6). The
method of RP-HPLC for the determination of impurities in AGLT-BZ was proved to be
precise, accurate, robust and reliable. Three batches of self-made bulk drug and three
dosages of commercial tablets were detected with this method.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).tical University, No.103, Wenhua Road, Shenyang 110016, China. Tel./fax: þ86 24 23986522.
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Recent years, diabetes has been a serious disease affecting
the patients around the world. According to International
Diabetes Federation (IDF), there are totally 382 million dia-
betes patients in 2013. And this number will rise to 592
million by 2035 [1]. Type 2 diabetes is a chronic disease and
progressive disease usually characterized by resistance of
insulin and defunction of b-cell [2e4]. Dipeptidyl peptidase-4
(DPP-4) is an enzyme, which is widely distributed in living
organisms and blood circulation and could inactivate
endogenous glucagon-like peptide-1 (GLP-1), an insulin tropic
hormones playing an important role in promoting insulin
secretion, inhibiting glucagon secretion, delaying gastric
emptying, enhancing satiety and moderating food intake
[5e9].
Alogliptin, active ingredient of 2-[6-[3(R)-Aminopiperidin-1-
yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-
ylmethyl] benzonitrile Benzoate, is a novel, potent and highly
selective DPP-4 inhibitor [10]. It has been developed into a
commodity firstly by Takeda Pharmaceutical Company Limited
and on list in Japan and America in 2010 and 2013, respectively.
Strict control of impurities is necessary for the
manufacturing of drug products. These impurities may be
present in the materials, formed as by-products during the
process of production or appear as degradation productsFig. 1 e The synthesisduring storage. Both actual and potential impurities should
be studied and detected by a reliable and convenient
method. Though a method was referred to in a patent of
Takeda, the practicability of this method has not been
verified [11]. Few studies about the related substances of
AGLT-BZ have been reported. It is necessary not only to find
the potential impurities according to the drug characteristic
and synthesis route shown in Fig. 1, but to find a convenient,
accuracy and sensitive method to detect them. The impu-
rities of AGLT-BZ studied in this paper were named as
compounds A, B, C, D, E, F and G shown in Table 1,
respectively.2. Materials and methods
2.1. Materials
Alogliptin Benzoate bulk drug were synthesized in our labo-
ratory. Three dosages of commercial tablets (Nesina) were
purchased from Takeda (Japan). Impurity standards A, B, C, D,
E, F and G were obtained from Chiral-Tech Pharmaceutical
Co., Ltd (Beijing, China, purity >98%). Table 1 shows the
chemical structures of AGLT-BZ and its known impurities.
HPLC-grade acetonitrile and trifluoroacetic acid were pur-
chased from Concord (Tianjin, China) and Kelmel (Tianjin,route of AGLT-BZ.
Table 1 e Structures of impurities in alogliptin.
Name Molecular
formula
Structure
Impurity A C10H16N4O2
Impurity B C18H23N5O3
Impurity Ca C17H19N5O2
Impurity D C23H25N7O4
Impurity E C17H19N5O2
Impurity F C25H22N6O3
Impurity G C30H31N8O4
a Impurity C exists as a benzoate salt.
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 1 5 2e1 5 8154China), respectively. Water for HPLC analysis was purified by
the Yarong water purification system (Yarong Corp, Shanghai,
China) and filtered with 0.22-mm membranes. All other re-
agents were of analytical grade.2.2. Instrumentation and chromatographic method
The HPLC system (Hitachi Chromaster, Japan) consisted of a
5110 quaternary pump, a 5210 auto sampler, a 5310 column
compartment, and a 5410 UV detector and 5430 diode array-
detector (DAD) operated at 278 nm. The chromatographic
datum were collected and analyzed by the use of Hitachi
Chromaster System software. Separation was achieved under
gradient elution on a spherical silica-basedAngilent Zobax SB-
CN column, 250 4.6mm, particle size 5.0 mmfromUSAwith a
flow rate of 1.0ml/min at 278 nm and the column temperature
was 35 C. The injection volumewas 20 ml. Amixture consisted
of water/acetonitrile/trifluoroacetic acid 1900:100:1 v/v (solu-
tion A) and acetonitrile/water/trifluoroacetic acid 1900:100:1
v/v (solution B). The gradient program started at 99% solution
A and then solution B was increased linearly from 1% to 25%
for a 30-min period, and in the next 20-min, solution B was
increased linearly from 25% to 90%. A 9-min re-equilibration
at 99% for solution A was followed by a 1-min return ramp
to solution A 99%.
The 1H-NMR spectrometry experiments of impurities were
conducted on a BRUKER AV500-III (Karlsruhe, Germany; 1H
500 MHz) and Mass spectrometry experiments were per-
formed on a LC/MS 2020 (Shimadzu, Japan).2.3. Preparation of standard solutions
2.3.1. Preparation of AGLT-BZ standards
AGLT-BZ stock solution of 1 mg/mL was prepared in diluent
solution (water/trifluoroacetic acid 200:1 v/v) using the AGLT-
BZ reference standard (self-made). Calibration standard so-
lutions of 0.5 mg/ml were prepared by diluting the stock
solution.
2.3.2. Preparation of impurity standards
Impurity sock solution of 200 mg/ml was prepared by in solu-
tion using the impurity reference standard. Work solutions
using in this study were prepared by serious dilution with
ranging from 50 to 1000 ng/ml.
2.3.3. Sample preparation of drug bulk and commercial
tablets
Solutions of bulk drug were prepared samely with AGLT-BZ
standards. And the solutions of commercial tablets were
prepared as follows: add 10 tablets into a suitable volumetric
flask (250 ml for dosage 34 mg, 100 ml for dosage 17 mg and
50 ml for dosage 8.5 mg), then add right amount solvent so-
lution (water/trifluoroacetic acid 200:1 v/v), keep them under
ultrasound for 30 min and then dilute to corresponding vol-
umes. Then centrifuge for 10 min at 3500 r.p.m. The sample
solutions were finally obtained by diluting the supernatant to
0.5 mg/ml with a specific dilution ratio according to the
dosage.
Fig. 2 e Pathways of every impurity (SM stands for Starting Material, IM stands for Intermediate, the Arabic number stands
for the compound from Fig. 1).
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In order to examine the selectivity of the method and study
the degradation of the bulk drug: 50 mg AGLT-BZ was
destroyed with proper amount of HCl (0.1 M) or NaOH (0.1 M)
at 75 C for 30 min. Oxidation of AGLT-BZ was achieved by the
use of 15% H2O2 for 30 min at 75 C and thermodestruction of
bulk drug was operated on a electric resistance furnace. The
drug in solid state was exposed under 4000 l light at room
temperature for 15 days. Before being detected, the acid-
stressed and base-stressed samples were neutralized with
base and acid, respectively.
All solutions were filtered, prior to the use, through 0.22-
mm pore size filters.Table 2 e 1H-NMR spectrum datum of alogliptin and its impur
Aloglitptin Impurity A
1.26e2.73 (8H, m, CH2*4) 1.23e3.21 (8H, m, CH2*4)
3.06 (1H, s, 1-CH) 3.35 (3H, s, CH3)
3.32 (3H, s, CH3) 3.57 (1H, m, 1-CH)
5.29 (2H, s, CH2) 5.08 (1H, s, 7-CH)
5.38 (1H, s, 7-CH)
7.12e7.68 (4H, m, Ph-H)
Impurity D Impurity E
1.35e1.79 (4H, m, CH2*2) 1.23e3.13 (8H, m, CH2*4)
2.69 (2H, s, CH2) 3.25 (3H, s, CH3)
3.16e3.18 (2H, m, CH2) 3.46e3.49 (1H, m, 1-CH)
3.04 (3H, s, CH3) 4.42e4.52 (2H, m, CH2)
3.34 (3H, s, CH3) 4.57 (1H, s, 7-CH)
3.56e3.67 (2H, m, CH2) 5.30 (1H, s, 70-CH)
4.58 (1H, s, 7-CH) 5.38e5.43 (2H, m, CH2)
4.91 (1H, s, 70-CH) 7.19e7.61 (8H, m, Ph-H)
5.24e5.30 (2H, m, CH2)
5.55e5.60 (1H, m, 1-CH)
6.86e7.67 (4H, m, Ph-H)
10.55 (1H, s, NH)2.4. Method validation
The validation study was consisted of selectivity, accuracy,
precision, robustness, limit of detection (LOD) and limit of
quantitation (LOQ), as well as linearity.2.5. Analysis of AGLT-BZ bulk drug and its formulations
Three batches of self-made bulk drug and three dosages of
commercial products were analyzed by this procedure. The
amount of each impurity was calculated by comparing the
peak areas by external standard method.ities.
Impurity B Impurity C
1.27e2.90 (8H, m, CH2*4) 1.65e3.26 (8H, m, CH2*4)
3.01 (1H, m, 1-CH) 3.58e3.61 (1H, m, 1-CH)
3.32 (3H, s, CH3) 5.16e5.23 (2H, m, CH2)
5.33 (2H, s, CH2) 5.33 (1H, s,7- CH)
5.37 (1H, s, 7-CH) 7.30e7.95 (9H, m, Ph-H)
7.05e7.55 (4H, m, Ph-H)
Impurity F Impurity G
1.26e2.88 (8H, m, CH2*4) 1.24e1.86 (4H, m, CH2*2)
3.28 (3H, s, CH3) 3.04 (1H, s, 1-CH)
4.29 (1H, s, 1-CH) 3.16e3.18 (2H, m, CH2)
5.30 (2H, s, CH2) 3.31 (3H, s, CH3)
5.39 (1H, s, 7-CH) 3.39 (2H, m, CH2)
7.20e7.68 (9H, m, Ph-H) 4.79 (1H, s, CH)
5.03e5.09 (2H, d, CH2)
5.22e5.27 (2H, d, CH2)
5.75 (1H, s, CH)
6.99e7.86 (8H, m, Ph-H)
Fig. 3 e Separation of alogliptin with benzoate and
impurities (Peaks: 1 ¼ A, 2 ¼ B, 3 ¼ C, 4 ¼ benzoate,
5 ¼ alogliptin, 6 ¼ D, 7 ¼ E, 8 ¼ F and 9 ¼ G).
Fig. 4 e Chromatograms of forced degradation test (A. impuritie
for 0.5 h; D. heat; E. 4000 lx light for 15 days; F. 15% H2O2 for 0.
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3.1. Pathway of each impurity
Impurities appear mainly from two ways: brought in during
productive process and degraded from the main drug during
storage process. During the reaction, starting materials or
intermediates remained or their by-products with main drug
may become impurities. Additionally, nomatter in the form of
bulk drug or pharmaceutics, drug may degrade through
various pathways such as oxidation, light, heat and acid/base.
Fig. 2 shows that the pathways of impurities in AGLT-BZ.3.2. Confirmation of unknown impurities
Impurity A: a brown solid; UV lmax 271 nm;
1H NMR, see
Table 2; ESI-MS m/z 225.1 [M þ H]þ.
Impurity B: a yellow oil; UV lmax 274 nm;
1H NMR, see Table
2; ESI-MS m/z 358.1 [M þ H]þ.s A, B, C, D, E, F and G; B. 0.1 M HCl for 0.5 h; C. 0.1 M NaOH
5 h).
Table 3 e LODs and LOQs of Alogliptin and each impurity.
Alogliptin Impurity A Impurity B Impurity C Impurity D Impurity E Impurity F Impurity G
LOD (ng/ml) 8.32 1.69 8.33 6.61 4.96 12.73 6.80 5.11
LOQ (ng/ml) 24.96 5.06 25.00 19.82 14.89 38.27 20.40 15.35
Table 5 e Recoveries of each target substance at 0.4, 0.5
and 0.6 mg/ml.
Impurity Average recovery at different concentrations
(%)
0.4 mg/ml 0.5 mg/ml 0.6 mg/ml
A 99.10 99.25 100.92
B 99.41 103.65 100.45
C 101.71 101.03 101.84
D 100.34 99.28 100.65
E 97.43 97.28 101.89
F 103.78 103.77 103.33
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1H NMR, see
Table 2; ESI-MS m/z 326.1 [M þ H]þ.
Impurity D: a yellow solid; UV lmax 268 nm;
1H NMR, see
Table 2; ESI-MS m/z 464.2 [M þ H]þ.
Impurity E: a yellow solid; UV lmax 275 nm;
1H NMR, see
Table 2; ESI-MS m/z 455.2 [M þ H]þ.
Impurity F: a white solid; UV lmax 274 nm;
1H NMR, see
Table 2; ESI-MS m/z 444.2 [M þ H]þ.
Impurity G: a yellow solid; UV lmax 268 nm;
1H NMR, see
Table 2; ESI-MS m/z 579.2 [M þ H]þ.
The ESI-MS results and 1H NMR spectrum data agree with
the structure data in Table 2.
3.3. Selection of HPLC conditions
Thismethodwas established according to the patent of Takeda
Pharmaceutical Company Limited [11]. In order to achieve the
separation of all substances, we firstly compared C18 with CN
columns and different mobile phases with different pH and
proportions. Finally, an Angilent Zobax SB-CN column
(250  4.6 mm; 5 mm) with water/acetonitrile/trifluoroacetic
acid was chosen as the method for the future study, because it
provided a better separation, column efficiency, acceptable
peak shape and a short analysis time. Trifluoroacetic acid
provided an acidic condition to guarantee the benzoic acid
emerging with the form of molecules and having a good sep-
aration with AGLT. To have a high sensitivity for each target
analyte, a wavelength of 278 nm was used. Giving consider-
ation to the separations and run time, the flow rate and column
temperaturewere set at 1.0ml/min and 35 C, respectively, and
a gradient elution was finally chosen. Fig. 3 shows the best
separation of AGLT-BZ with its potential impurities.
3.4. Validation assay
3.4.1. Method selectivity
Fig. 2 shows that resolution between alogliptin, benzoate and
impurities can meet the requirement of baseline separation
(Resolution > 1.5).Table 4 e Results for the calibration curves of each
impurity.
Impurities Concentration
range (ng/ml)
Equation of the
calibration plot
R2
A 50e1000 y ¼ 122.75x þ 211.98 0.9996
B 100e1000 y ¼ 33.509x  294.56 0.9996
C 100e1000 y ¼ 48.055x þ 82.304 0.9996
D 100e1000 y ¼ 65.441x  1189.9 0.9992
E 150e1000 y ¼ 32.501x  489.16 0.9991
F 100e1000 y ¼ 36.834x þ 189.02 0.9991
G 100e1000 y ¼ 39.530x  357.30 0.9998The selectivity of this method was further assessed by a
series of forced degradation tests, including acid or base
degradation test, high temperature test, oxidant degradation
test and light test. Fig. 4 indicates that both known impurities
and unknown impurities have good separations with alog-
liptin and benzoate (Resolution > 1.5).
3.4.2. Limit of Detection (LOD)/Limit of Quantitation (LOQ)
The LOD and LOQ were determined at a signal-to-noise ratio
of 3:1 and 10:1 by injecting a series of diluted solutions with
known concentrations, respectively. Table 3 shows the
detailed results of the LODs and LOQs.
3.4.3. Linearity
Linear regression analysis of each target substances was
performed using external standard method by injecting a se-
ries of solutions with different concentrations from 100 to
1000 ng/ml for impurities B, C, D, F and G, from 150 to 1000 ng/
ml for impurity E, and from 50 to 1000 ng/ml for impurity A.
Table 4 shows the linear responses for the peak areas against
concentrations obtained for each impurity with correlation
coefficients (R2) ranging from 0.9991 to 0.9998.
3.4.4. Accuracy
Accuracy was determined by adding known amount of im-
purities into AGLT-BZ solutions. Then the recovery of the drug
was determined. The final concentrations being detected forG 102.94 102.89 97.04
Table 6 e Results of the precision for each impurity.
Impurity Retention time RSD
(%)
Peak area RSD
(%)
A 0.41 0.55
B 0.03 1.17
C 0.03 0.48
D 0.06 1.71
E 0.07 1.92
F 0.04 0.59
G 0.04 0.81
Table 7 e Results of detection of self-made bulk drug and commercial tablets testing using HPLC method.
Self-made bulk drug Commercial tablets
Batch/Dosage Batch 1 Batch 2 Batch 3 8.5 mg 17 mg 34 mg
Impurity A <0.02% n.d. n.d. <0.02% n.d. n.d.
Impurity B n.d. n.d. n.d. <0.02% <0.02% <0.02%
Impurity C <0.02% <0.02% <0.02% <0.02% n.d. n.d.
Impurity D n.d. n.d. n.d. 0.06% 0.02% <0.02%
Impurity E n.d. n.d. n.d. n.d. <0.02% n.d.
Impurity F n.d. n.d. n.d. n.d. n.d. n.d.
Impurity G <0.02% <0.02% <0.02% <0.02% <0.02% <0.02%
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Table 5 shows that the average recovery for all impurities
ranges from 97.04 to 103.78.
3.4.5. Precision
The precision of the method was obtained by injecting the
same preparation of impurities sample solutions six times
continuously. Table 6 shows the RSD% of peak areas and
retention times for each impurity.
3.4.6. Solution stability
The impurities solution were left at room temperature and
injected at 0-, 2-, 4-, 6-, 8-, 10-, 12-h time intervals. The con-
sistency at each interval was calculated by the changes of
peak area. The results indicate all the impurities except im-
purity A are stable in 12 h.
3.4.7. Robustness
To evaluate the robustness of the analytical HPLCmethod, the
changes on flow rate of mobile phase (±20%), column tem-
perature (±5 C), detection wavelength (±5 nm) and two
different brand columns were made. And when having each
little change for the chromatographic condition, it had still
good separations between each target analyte and none of the
change caused a significant effect on the system parameters
like retention time, peak area, theoretical and tailing factor.
3.5. Batch results
Three batch self-made bulk drug and three dosages com-
mercial tablets were tested using this HPLC method. Table 7
indicates that no impurity was found to be above 0.1%. Only
impurity F was not found in all the samples. Impurity A, C and
G were found in self-made bulk drug.4. Conclusion
Seven new impurities of Alogliptin Benzoate were detected
by a developed, precise, fast, accurate HPLC method. All theimpurities were confirmed by ESI-MS and 1H-NMR. The
method can obtain a good and reliable separation for each
target compound by a series of forced degradation tests. The
method may be used to assess the quality of Alogliptin
tablets.r e f e r e n c e s
[1] Guariguata L, Whiting DR, Hambleton I, et al. Global
estimates of diabetes prevalence for 2013 and projections for
2035. Diabetes Res Clin Pract 2014;103(2):137e149.
[2] Meier JJ. Beta cell mass in diabetes: a realistic therapeutic
target? Diabetologia 2008;51(5):703e713.
[3] Kaneto H, Katakami N, Matsuhisa M, et al. Role of reactive
oxygen species in the progression of type 2 diabetes and
atherosclerosis. Mediat Inflamm 2010;2010:1e12.
[4] Robertson RP, Harmon J, Tran POT, et al. b-cell glucose
toxicity, lipotoxicity, and chronic oxidative stress in type 2
diabetes[J]. Diabetes 2004;53(suppl 1):S119e24.
[5] Drucker DJ. Glucagon-like peptides. Diabetes
1998;47:159e169.
[6] Nauck MA. Is glucagon-like peptide 1 an incretin hormone?
[J]. Diabetologia 1999;42(3):373e379.
[7] Wang Y, Egan JM, Raygada M, et al. Glucagon-like peptide-1
affects gene transcription and messenger ribonucleic acid
stability of components of the insulin secretory system in
RIN 1046-38 cells. Endocrinology 1995;136:4910e4917.
[8] Kieffer TJ, McIntosh CH, Pederson RA. Degradation of
glucose-dependent insulinotropic polypeptide and truncated
glucagon-like peptide 1 in vitro and in vivo by dipeptidyl
peptidase IV. Endocrinology 1995;136(8):3585e3596.
[9] Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both
subcutaneously and intravenously administered glucagon-
like peptide I are rapidly degraded from the NH2-terminus in
type II diabetic patients and in healthy subjects. Diabetes
1995;44(9):1126e1131.
[10] Feng J, Zhang Z, Wallace MB, et al. Discovery of alogliptin: a
potent, selective, bioavailable, and efficacious inhibitor of
dipeptidyl peptidase IV. J Med Chem 2007;50(10):2297e2300.
[11] Koyama H, Yamamoto K. Solid preparation comprising
alogliptin and metformin hydrochloride: U.S. Patent
Application 12/452,705[P]. 2008-7e16.
